Becton, Dickinson and Company $BDX Shares Bought by Patriot Financial Group Insurance Agency LLC

Patriot Financial Group Insurance Agency LLC raised its position in Becton, Dickinson and Company (NYSE:BDX) by 25.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,301 shares of the medical instruments supplier’s stock after acquiring an additional 2,887 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Becton, Dickinson and Company were worth $2,463,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Northcape Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after acquiring an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock valued at $225,000 after acquiring an additional 53 shares in the last quarter. Brady Family Wealth LLC boosted its stake in Becton, Dickinson and Company by 1.2% in the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock valued at $989,000 after acquiring an additional 53 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after buying an additional 53 shares during the last quarter. Finally, Horizon Bancorp Inc. IN raised its holdings in shares of Becton, Dickinson and Company by 10.9% in the first quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 56 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock valued at $562,036 in the last ninety days. 0.36% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Morgan Stanley raised their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price target for the company. Finally, Argus raised their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Trading Up 0.3%

Shares of Becton, Dickinson and Company stock opened at $191.43 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a fifty day moving average price of $188.87 and a 200 day moving average price of $187.95. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The stock has a market cap of $54.87 billion, a PE ratio of 34.43, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter last year, the company posted $3.50 earnings per share. The firm’s revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.